RESEARCHER PROFILE

Devya Khaim Chandani

← Back to Shaheed Mohtarma Benazir Bhutto Medical University

D

Shaheed Mohtarma Benazir Bhutto Medical University

Pulmonary Hypertension Research and TreatmentsComplement system in diseasesDiabetes, Cardiovascular Risks, and LipoproteinsHIV/AIDS Research and InterventionsHIV Research and Treatment

Devya Khaim Chandani works in Pulmonary Hypertension Research and Treatments, Complement system in diseases, Diabetes, Cardiovascular Risks, and Lipoproteins, HIV/AIDS Research and Interventions, HIV Research and Treatment. Recorded institutional associations include Shaheed Mohtarma Benazir Bhutto Medical University.

15Publications
27Citations
3H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis

    2025 · 8 citations

  2. Olezarsen: FDA approval and clinical impact in familial chylomicronemia syndrome (FCS)

    2025 · 6 citations

  3. Bruton’s tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy

    2025 · 6 citations

  4. OUTCOMES OF RECONSTRUCTION WITH VASCULARIZED VS NON-VASCULARIZED BONE GRAFT AFTER RESECTION OF BONE TUMOURS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    2023 · 3 citations

  5. Assessment of safety of niraparib maintenance therapy in epithelial ovarian cancer: an updated systematic review and meta-analysis of randomized control trials

    2025 · 1 citations

  6. Breaking barriers in HIV management: the rise of long-acting lenacapavir

    2025 · 1 citations

  7. Measles resurgence in Texas: a public health wake-up call

    2025 · 1 citations

  8. Efficacy and Safety of Pioglitazone Added to Metformin and SGLT2 Inhibitors in Type 2 Diabetes: An Updated Systematic Review and Meta-analysis

    2026 · 1 citations

  9. Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria

    2025 · 0 citations

  10. Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA)

    2025 · 0 citations

  11. Pulmonary arterial hypertension and the limits of convenience: a critical look at yutrepia

    2025 · 0 citations

  12. Enflonsia (clesrovimab) and the future of RSV lower respiratory tract disease prevention in neonates:[RETRACTED]

    2026 · 0 citations

  13. Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway

    2026 · 0 citations

  14. Acute quadriparesis revealing Gitelman syndrome: a case report

    2026 · 0 citations

  15. Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials

    2026 · 0 citations

← Return to the university profile